Common heart attack drug doesn’t work and may raise risk of death for some women, new studies say

Groundbreaking research presented at the European Society of Cardiology Congress and published in the European Heart Journal indicates that beta-blockers, long a standard post-heart attack treatment, offer no benefit for the vast majority of patients with preserved heart function (ejection fraction >50%). Crucially, women in this cohort experienced significantly higher risks of re-hospitalization, subsequent heart attacks, and nearly triple the mortality when treated with the drug. These findings, which contradict current guidelines leading to 80% of patients receiving the drug, are expected to reshape international clinical protocols, potentially impacting pharmaceutical demand and healthcare strategies for cardiovascular care.

Analysis

Groundbreaking clinical research, published in leading medical journals like The New England Journal of Medicine and the European Heart Journal, fundamentally challenges the 40-year standard of care for post-myocardial infarction treatment. The REBOOT trial, a large-scale study involving 8,505 patients, found no clinical benefit in prescribing beta-blockers to patients with preserved heart function (left ventricular ejection fraction > 50%), a group that now represents the majority of heart attack survivors. More critically, the study identified a significant and harmful sex-specific effect, with women in this cohort experiencing a nearly threefold increase in mortality and a higher risk of re-hospitalization when treated with beta-blockers. Given that an estimated 80% of post-heart attack patients in the US, Europe, and Asia currently receive this therapy under existing guidelines, these findings are poised to trigger a substantial revision of international treatment protocols. While the drug remains the standard of care for patients with significant heart damage (ejection fraction < 40%) and shows a 25% risk reduction for those with mild damage (40-50% EF), the impending guideline changes will dramatically narrow the addressable market for this drug class in one of its primary indications.

Key Decisions for Investors

• Investors should re-evaluate exposure to pharmaceutical companies with significant revenue from generic or branded beta-blockers, as a major revision of clinical guidelines could substantially contract the addressable market for post-heart attack treatment.
• Monitor for emerging investment opportunities in companies developing alternative post-myocardial infarction therapies or advanced cardiac diagnostic tools, as the research creates a treatment gap and highlights the need for more precise patient stratification based on ejection fraction and sex.
• The primary catalyst for a shift in prescribing patterns will be official updates from cardiology societies and regulatory bodies; therefore, closely tracking their announcements is critical before making significant portfolio adjustments based on this research.